trastuzumab,tucatinib
Seagen,Roche
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'tucatinib', 'crcsm']
tucatinib plus trastuzumab elicits responses in crossover cohort in her2+ mcrc #esmo2022 #crcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.